CytoMed Therapeutics Limited Ordinary Shares earnings per share and revenue
On 14 de nov. de 2025, GDTC reported earnings of -- USD per share (EPS) for Q2 25, -- the estimate of -0.04 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 132.60 mil, with a --% difference.
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.04 USD, with revenue projected to reach 132.60 mil USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were CytoMed Therapeutics Limited Ordinary Shares's earnings and revenue for the latest quarter Q2 2025?
For Q2 2025, CytoMed Therapeutics Limited Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to CytoMed Therapeutics Limited Ordinary Shares's Q2 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is CytoMed Therapeutics Limited Ordinary Shares expected to report next?
The next earning report is scheduled for 28 de abr. de 2026.
What are the forecasts for CytoMed Therapeutics Limited Ordinary Shares's next earnings report?
Based on 3
analistas, CytoMed Therapeutics Limited Ordinary Shares is expected to report EPS of -$0.04 and revenue of $132.60K for Q4 2025.